Nemes Rush Group’s Gilead Sciences GILD Stock Holding History

Nemes Rush Group’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.75M	Buy	26,940 +168	+0.6%	+$23.5K	0.36%	62
2025 Q4	$3.29M	Buy	26,772 +264	+1%	+$32.1K	0.31%	62
2025 Q3	$2.94M	Buy	26,508 +4,158	+19%	+$473K	0.29%	61
2025 Q2	$2.48M	Buy	22,350 +21,612	+2,928%	+$2.3M	0.27%	66
2025 Q1	$82.7K	Hold	738	–	–	0.01%	271
2024 Q4	$68.2K	Sell	738 -5,858	-89%	-$527K	0.01%	273
2024 Q3	$483K	Buy	6,596 +5,715	+649%	+$436K	0.07%	117
2024 Q2	$60.4K	Sell	881 -5,740	-87%	-$383K	0.01%	247
2024 Q1	$485K	Sell	6,621 -23,220	-78%	-$1.79M	0.07%	119
2023 Q4	$2.42M	Sell	29,841 -230	-0.8%	-$17.9K	0.39%	55
2023 Q3	$2.25M	Sell	30,071 -290	-1%	-$22.3K	0.41%	56
2023 Q2	$2.34M	Buy	+30,361	New	+$2.42M	0.41%	56

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Nemes Rush Group's GILD Position: Q1 2026 in Review

Nemes Rush Group increased its Gilead Sciences (GILD) stake by 0.63% in Q1 2026, buying an estimated $23.5K and bringing the position to 26,940 shares worth $3.75M. The position accounts for 0.36% of the portfolio, ranked #62.

Nemes Rush Group first reported a position in GILD in Q2 2023 and has held it in 12 quarters since. 2,310 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

Nemes Rush Group held 26,940 shares of Gilead Sciences worth $3.75M as of Q1 2026.
Nemes Rush Group bought 168 Gilead Sciences shares in Q1 2026, an estimated $23.5K.
Gilead Sciences made up 0.36% of Nemes Rush Group's portfolio in Q1 2026, its #62 holding.
Nemes Rush Group first reported a position in Gilead Sciences in Q2 2023 and has held it in 12 quarters since.
2,310 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Nemes Rush Group's 13F filing for Q1 2026, filed 21 Apr 2026.